Directed by the world’s leading experts in psychedelic treatment, Auvega’s scientific advisory board is currently engaging leading universities and research teams.
Auvega is powered by innovation and exploring new and emergent markets in alternative medicine, supplements, and psychedelic pharmacology.
American adults suffer from a form of mental illness
the estimated cost of depression to the global economy
estimated global cost of mental health conditions in 2030 by the World Economic Forum(up from $2.5 trillion in 2010)
people die every day from opioid abuse
Over 7000 Years in the making
Canadian Health Minister Patty Hajdu approved the use of psilocybin mushrooms for four people with incurable cancer. This was the first time that an exemption to the Controlled Drugs and Substances Act has been granted for the use of mushrooms.
Pending approval of regulatory change, Auvega Labs Inc. intends to support practitioners in helping their patients obtain Special Access to psychedelic-assisted therapies for a range of conditions and delivering these through the clinics.
Health Canada has posted its Notice of Intent, subject to public consultation, to revise its Special Access Program to allow legal access to psilocybin and MDMA outside clinical trials, while the substances await formal approvals.
Auvega Labs Inc. supports Health Canada’s leadership and stands in solidarity with the individuals and organizations who have advocated to increase safe and evidence-based accessibility. By working together and supporting evidence-based approaches to mental health, psychedelic-assisted psychotherapy can become a routine part of the healthcare system.